Novel Pooling Strategies for Genetic Testing, with Application to Newborn Screening

References

• Abdalhamid B, Bilder CR, McCutchen EL, Hinrichs SH, Koepsell SA, Iwen PC (2020) Assessment of specimen pooling to conserve SARS CoV-2 testing resources. Amer. J. Clin. Pathol. 153(6):715–718. 10.1093/ajcp/aqaa064Crossref, Google Scholar
• Accurso FJ, Sontag MK, Wagener JS (2005) Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J. Pediatr. (Suppl 3):S37–S41.Crossref, Google Scholar
• Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) (2018) Recommended uniform screening panel core conditions. Accessed June 2020. https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/rusp-uniform-screening-panel.pdf.Google Scholar
• American Red Cross (2021) What happens to donated blood. Accessed June 2021. https://www.redcrossblood.org/donate-blood/blood-donation-process/what-happens-to-donated-blood.html.Google Scholar
• Aprahamian H, Bish EK, Bish DR (2018) Adaptive risk-based pooling in public health screening. IISE Trans. 50(9):753–766.Crossref, Google Scholar
• Aprahamian H, Bish DR, Bish EK (2019) Optimal risk-based group testing. Management Sci. 65(9):4365–4384.Link, Google Scholar
• Aprahamian H, Bish DR, Bish EK (2020) Optimal group testing: Structural properties and robust solutions, with application to public health screening. INFORMS J. Comput. 32(4):895–911.Abstract, Google Scholar
• Baby’s First Test (2019) Accessed June 2020. http://www.babysfirsttest.org/newborn-screening/states.Google Scholar
• Baker MW, Atkins AE, Cordovado SK, Hendrix M, Earley MC, Farrell PM (2016) Improving newborn screening for cystic fibrosis using next-generation sequencing technology: A technical feasibility study. Genet. Med. 18(3):231–238.Crossref, Google Scholar
• Bang-Jensen J, Gutin GZ (2008) Digraphs: Theory, Algorithms and Applications (Springer Science & Business Media, Springer, London).Google Scholar
• Bellman R (1958) On a routing problem. Quart. Appl. Math. 16(1):87–90.Crossref, Google Scholar
• Borowitz D, Parad RB, Sharp JK, Sabadosa KA, Robinson KA, Rock MJ, Farrell PM, et al. (2009) Cystic fibrosis foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J. Pediatr. 155(6):S106–S116.Crossref, Google Scholar
• Boyle MP, Boeck KD (2013) A new era in the treatment of cystic fibrosis: Correction of the underlying CFTR defect. Lancet Respir. Med. 1(2):158–163.Crossref, Google Scholar
• Brandeau ML (2004) Allocating Resources to Control Infectious Diseases (Springer US, Boston, MA), 443–464.Google Scholar
• California Department of Public Health (CDPH) (2019) Genetic disease screening program. Accessed June 2020. https://www.cdph.ca.gov/Programs/CFH/DGDS/CDPH%20Document%20Library/FY%202019-20%20GDSP%20November%20Estimate%20%201.9.19%20DOF%20Final.pdf.Google Scholar
• Campbell PW, White TB (2005) Newborn screening for cystic fibrosis: An opportunity to improve care and outcomes. J. Pediatr. (Suppl 3):S2–S5.Crossref, Google Scholar
• CFTR2 (2020) Accessed April 2020. https://www.cftr2.org/.Google Scholar
• Chakravarty A, Orlin J, Rothblum U (1982) A partitioning problem with additive objective with an application to optimal inventory groupings for joint replenishment. Oper. Res. 30(5):1018–1022.Link, Google Scholar
• Cormen TH, Leiserson CE, Rivest RL, Stein C (2009) Introduction to Algorithms (MIT Press, Cambridge, MA).Google Scholar
• Cunningham J, Taussig L (2013) An Introduction to Cystic Fibrosis for Patients and Their Families, 6th ed. (Cystic Fibrosis Foundation).Google Scholar
• Currier RJ, Sciortino S, Liu R, Bishop T, Koupaei RA, Feuchtbaum L (2017) Genomic sequencing in cystic fibrosis newborn screening: what works best, two-tier predefined CFTR mutation panels or second-tier CFTR panel followed by third-tier sequencing? Genet. Med. 19(10):1159–1163.Crossref, Google Scholar
• Cutting GR (2013) Chapter 58 - Cystic Fibrosis. Rimoin D, Pyeritz R, Korf B, eds. Emery and Rimoin’s Principles and Practice of Medical Genetics (Academic Press, Oxford, UK), 1–54.Crossref, Google Scholar
• Cystic Fibrosis Foundation (2009) All fifty states to screen newborns for cystic fibrosis by 2010. Accessed June 2020. https://www.cff.org/About-Us/Media-Center/Press-Releases/All-Fifty-States-to-Screen-Newborns-for-Cystic-Fibrosis-by-2010/.Google Scholar
• Cystic Fibrosis Foundation (2017) Sweat test. Accessed June 2021. https://www.cff.org/What-is-CF/Testing/Sweat-Test/.Google Scholar
• Cystic Fibrosis Foundation (2019) Carrier testing for cystic fibrosis. Accessed in June 2020. https://www.cff.org/What-is-CF/Testing/Carrier-Testing-for-Cystic-Fibrosis/.Google Scholar
• Deignan JL, Astbury C, Cutting GR, Del Gaudio D, Gregg AR, Grody WW, Monaghan KG, Richards S (2020) CFTR variant testing: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 22(8):1288–1295.Crossref, Google Scholar
• Dijkstra EW (1959) A note on two problems in connexion with graphs. Numer. Math. 1(1):269–271.Crossref, Google Scholar
• Dodd R, Notari E IV, Stramer S (2002) Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 42(8):975–979.Crossref, Google Scholar
• Dorfman R (1943) The detection of defective members of large populations. Ann. Math. Statist. 14(4):436–440.Crossref, Google Scholar
• Edouard S, Prudent E, Gautret P, Memish ZA, Raoult D (2015) Cost-effective pooling of DNA from nasopharyngeal swab samples for large-scale detection of bacteria by real-time PCR. J. Clin. Microbiol. 53(3):1002–1004.Crossref, Google Scholar
• Ehre C, Ridley C, Thornton DJ (2014) Cystic fibrosis: An inherited disease affecting mucin-producing organs. Internat. J. Biochem. Cell Biol. 52:136–145.Crossref, Google Scholar
• El Amine H, Bish EK, Bish DR (2018) Robust post-donation blood screening under prevalence rate uncertainty. Oper. Res. 66(1):1–17.Link, Google Scholar
• El Hajj H, Bish DR, Bish EK (2021a) Optimal genetic screening for cystic fibrosis. Oper. Res. 70(1):265–287.Google Scholar
• El Hajj H, Bish DR, Bish EK (2021b) Equity in genetic newborn screening. Naval Res. Logist. 68(1):44–64.Crossref, Google Scholar
• El Hajj H, Bish DR, Bish EK, Aprahamian H (2022) Screening multi-dimensional heterogeneous populations for infectious diseases under scarce testing resources, with application to covid-19. Naval Res. Logist. 69(1):3–20.Crossref, Google Scholar
• Eng W, LeGrys VA, Schechter MS, Laughon MM, Barker PM (2005) Sweat-testing in preterm and full-term infants less than 6 weeks of age. Pediatr. Pulmonol. 40(1):64–67.Crossref, Google Scholar
• Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG (2005) Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: Enough is enough! Pediatrics 147(Suppl 3):S30–S36.Crossref, Google Scholar
• Food and Drug Administration (2005) CFTR gene mutation detection systems - Class II special controls guidance for industry and FDA staff. Accessed June 2021. https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/cftr-gene-mutation-detection-systems-class-ii-special-controls-guidance-industry-and-fda-staff.Google Scholar
• Ford LR Jr (1956) Network flow theory. Technical report, Rand Corp, Santa Monica CA.Google Scholar
• Garcia G-GP, Lavieri MS, Jiang R, McCrea MA, McAllister TW, Broglio SP; CARE Consortium Investigators, et al. (2020) Data-driven stochastic optimization approaches to determine decision thresholds for risk estimation models. IISE Trans. 52(10):1098–1121.Crossref, Google Scholar
• Gilányi A, ed. (2009) Subadditive Functions (Birkhäuser Basel), 455–481.Google Scholar
• Grosse SD (2015) Showing value in newborn screening: Challenges in quantifying the effectiveness and cost-effectiveness of early detection of phenylketonuria and cystic fibrosis. Health Care (Don Mills). 3(4):1133–1157.Google Scholar
• Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, Wilfond BS (2004) Newborn screening for cystic fibrosis: Evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 53(40):1–36.Google Scholar
• Henneman L, Bramsen I, Van Kempen L, Van Acker MB, Pals G, Van Der Horst HE, Adèr HJ, Van Der Ploeg HM, Leo P (2003) Offering preconceptional cystic fibrosis carrier couple screening in the absence of established preconceptional care services. Public Health Genomics 6(1):5–13.Crossref, Google Scholar
• Hilsden RJ, Heitman SJ, Mizrahi B, Narod SA, Goshen R (2018) Prediction of findings at screening colonoscopy using a machine learning algorithm based on complete blood counts (colonflag). PLoS One 13:1–9, 11. 10.1371/journal.pone.0207848Crossref, Google Scholar
• Hughes EE, Stevens CF, Saavedra-Matiz CA, Tavakoli NP, Krein LM, Parker A, Zhang Z, et al. (2015) Clinical sensitivity of cystic fibrosis mutation panels in a diverse population. Hum. Mutat. 37(2):201–208.Crossref, Google Scholar
• Hwang FK (1975) A generalized binomial group testing problem. J. Amer. Statist. Assoc. 70(352):923–926.Crossref, Google Scholar
• Johns Hopkins Medicine (2019) Cystic fibrosis and CF-related disorders NGS panel. Accessed June 2020. https://www.hopkinsmedicine.org/dnadiagnostic/tests/tests/cystic-fibrosis-and-cf-related-disorders-ngs-panel.Google Scholar
• Johnson MA, Yoshitomi MJ, Richards CS (2007) A comparative study of five technologically diverse CFTR testing platforms. J. Mol. Diagn. 9(3):401–407.Crossref, Google Scholar
• Kammesheidt A, Kharrazi M, Graham S, Young S, Pearl M, Dunlop C, Keiles S (2006) Comprehensive genetic analysis of the cystic fibrosis transmembrane conductance regulator from dried blood specimens–implications for newborn screening. Genet. Med. 8(9):557–562.Crossref, Google Scholar
• Kay DM, Maloney B, Hamel R, Pearce M, DeMartino L, McMahon R, McGrath E, et al. (2015) Screening for cystic fibrosis in New York state: Considerations for algorithm improvements. Eur. J. Pediatr. 175(2):181–193.Crossref, Google Scholar
• Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC (1989) Identification of the cystic fibrosis gene: Genetic analysis. Science 245(4922):1073–1080.Crossref, Google Scholar
• Kharrazi M, Yang J, Bishop T, Lessing S, Young S, Graham S, Pearl M, et al. (2015) Newborn screening for cystic fibrosis in California. Pediatrics 136(6):1062–1072.Crossref, Google Scholar
• Kim H-Y, Hudgens MG, Dreyfuss JM, Westreich DJ, Pilcher CD (2007) Comparison of group testing algorithms for case identification in the presence of test error. Biometrics 63(4):1152–1163.Crossref, Google Scholar
• Kim SY, Lee J, Sung H, Lee H, Han MG, Yoo CK, Lee SW, Hong KH (2020) Pooling upper respiratory specimens for rapid mass screening of COVID-19 by real-time RT-PCR. Emerg. Infect. Dis. 26(10):2469.Crossref, Google Scholar
• Kloosterboer M, Hoffman G, Rock M, Gershan W, Laxova A, Li Z, Farrell PM (2009) Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics 123(2):e338–e346.Crossref, Google Scholar
• Kosheleva K, Faulkner N, Robinson K, Umbarger M (2017) Validation of a novel copy number variant detection algorithm for CFTR from targeted next generation sequencing data. Fertil. Steril. 108(3):e269.Crossref, Google Scholar
• Krook A, Stratton IM, O’Rahilly S (1992) Rapid and simultaneous detection of multiple mutations by pooled and multiplex single nucleotide primer extension: Application to the study of insulin-responsive glucose transporter and insulin receptor mutations in non-insulin-dependent diabetes. Hum. Mol. Genet. 1(6):391–395.Crossref, Google Scholar
• Kuipers EJ, Rösch T, Bretthauer M (2013) Colorectal cancer screening-optimizing current strategies and new directions. Nat. Rev. Clin. Oncol. 10(3):130.Crossref, Google Scholar
• LeGrys VA (2002) Newborn screening for cystic fibrosis. Lab. Med. 33(3):212–213.Crossref, Google Scholar
• Lewis JL, Lockary VM, Kobic S (2012) Cost savings and increased efficiency using a stratified specimen pooling strategy for Chlamydia Trachomatis and Neisseria Gonorrhoeae. Sex. Transm. Dis. 39(1):46–48.Crossref, Google Scholar
• Lim RM, Silver AJ, Silver MJ, Borroto C, Spurrier B, Petrossian TC, Larson JL, Silver LM (2016) Targeted mutation screening panels expose systematic population bias in detection of cystic fibrosis risk. Genet. Med. 18(2):174.Crossref, Google Scholar
• Lutz AM, Willmann JK, Cochran FV, Ray P, Gambhir SS (2008) Cancer screening: A mathematical model relating secreted blood biomarker levels to tumor sizes. PLOS Med. 5:1–11.Crossref, Google Scholar
• Mattar ACV, Leone C, Rodrigues JC, Adde FV (2014) Sweat conductivity: An accurate diagnostic test for cystic fibrosis? J. Cyst. Fibros. 13(5):528–533.Crossref, Google Scholar
• McMahan CS, Tebbs JM, Bilder CR (2012) Informative Dorfman screening. Biometrics 68(1):287–296.Crossref, Google Scholar
• Mehta A (2007) A global perspective on newborn screening for cystic fibrosis. Curr. Opin. Pulm. Med. 13(6):510–514.Crossref, Google Scholar
• Nguyen NT, Aprahamian H, Bish EK, Bish DR (2019) A methodology for deriving the sensitivity of pooled testing, based on viral load progression and pooling dilution. J. Transl. Med. 17(1):252.Crossref, Google Scholar
• North Carolina State Laboratory of Public Health (NCLPH) (2016) Newborn screening: Reporting - cystic fibrosis. Accessed June 2020. https://slph.ncpublichealth.com/newborn/Reporting.asp.Google Scholar
• Nshimyumukiza L, Bois A, Daigneault P, Lands L, Laberge A-M, Fournier D, Duplantie J, et al. (2014) Cost effectiveness of newborn screening for cystic fibrosis: A simulation study. J. Cyst. Fibros. 13(3):267–274.Crossref, Google Scholar
• Phatarfod R, Sudbury A (1994) The use of a square array scheme in blood testing. Stat. Med. 13(22):2337–2343.Crossref, Google Scholar
• Pilcher CD, Westreich D, Hudgens MG (2020) Group testing for SARS-CoV-2 to enable rapid scale-up of testing and real-time surveillance of incidence. J. Infect. Dis. 222(6):903–909.Crossref, Google Scholar
• Rios M, Daniel S, Chancey C, Hewlett IK, Stramer SL (2007) West Nile virus adheres to human red blood cells in whole blood. Clin. Infect. Dis. 45(2):181–186.Crossref, Google Scholar
• Rosenberg MA, Farrell PM (2005) Assessing the cost of cystic fibrosis diagnosis and treatment. J. Pediatr. 147(3):S101–S105.Crossref, Google Scholar
• Rours G, Verkooyen R, Willemse H, van der Zwaan E, van Belkum A, de Groot R, Verbrugh H, Ossewaarde J (2005) Use of pooled urine samples and automated DNA isolation to achieve improved sensitivity and cost-effectiveness of large-scale testing for Chlamydia trachomatis in pregnant women. J. Clin. Microbiol. 43(9):4684–4690.Crossref, Google Scholar
• Sadeghzadeh S, Bish EK, Bish DR (2020) Optimal data-driven policies for disease screening under noisy biomarker measurement. IISE Trans. 52(2):166–180.Crossref, Google Scholar
• Schmidt M, Werbrouck A, Verhaeghe N, De Wachter E, Simoens S, Annemans L, Putman K (2020) A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium. Acta Clin. Belg. 75(3):212–220.Crossref, Google Scholar
• Schrijver I, Pique L, Graham S, Pearl M, Cherry A, Kharrazi M (2016) The spectrum of CFTR variants in nonwhite cystic fibrosis patients: implications for molecular diagnostic testing. J. Mol. Diagn. 18(1):39–50.Crossref, Google Scholar
• Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, et al. (2013) Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat. Genet. 45(10):1160–1167.Crossref, Google Scholar
• Steimle LN, Denton BT (2017) Markov Decision Processes for Screening and Treatment of Chronic Diseases (Springer International Publishing, Cham, Switzerland), 189–222.Crossref, Google Scholar
• Therrell BL, Hannon WH, Hoffman G, Ojodu J, Farrell PM (2012) Immunoreactive trypsinogen (IRT) as a biomarker for cystic fibrosis: Challenges in newborn dried blood spot screening. Mol. Genet. Metab. 106(1):1–6.Crossref, Google Scholar
• Tluczek A, Koscik RL, Farrell PM, Rock MJ (2005) Psychosocial risk associated with newborn screening for cystic fibrosis: Parents’ experience while awaiting the sweat-test appointment. Pediatrics 115(6):1692–1703.Crossref, Google Scholar
• Turgeon ML (2015) Linne & Ringsrud’s Clinical Laboratory Science-E-Book: The Basics and Routine Techniques (Elsevier Health Sciences, St. Louis).Google Scholar
• van den Akker-van ME, Dankert HM, Verkerk PH, Dankert-Roelse JE, et al. (2006) Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. Pediatrics 118(3):896–905.Crossref, Google Scholar
• van der Ploeg CP, van den Akker-van Marle ME, Vernooij-van Langen AMM, Elvers LH, Gille JJP, Verkerk PH, Dankert-Roelse JE; CHOPIN Study Group (2015) Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data. J. Cyst. Fibros. 14(2):194–202.Crossref, Google Scholar
• Wells J, Rosenberg M, Hoffman G, Anstead M, Farrell PM (2012) A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis. Pediatrics 129(2):e339–e347.Crossref, Google Scholar
• Willis MS (2012) Multiple positive sweat chloride tests in an infant asymptomatic for cystic fibrosis. Lab. Med. 43(2):1–5.Google Scholar
• Wisconsin State Laboratory of Hygiene (WSLH) (2018) Newborn blood screening panel of diseases: Cystic fibrosis. Accessed June 2020. http://www.slh.wisc.edu/clinical/newborn/health-care-professionals-guide/nbs-test-panel-of-diseases/#cf.Google Scholar